SYK · NYSE
Medical Devices · United States
Snapshot 2026-11-11 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2027-01-28 (provider estimate; issuer confirmation unavailable here).
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Company websiteQ3 2026
Published 2026-11-10
Q3 2026 REPORT HIGHLIGHTS
Stryker grows organically but cuts guidance as acquisition economics and the gap between GAAP and adjusted profit demand scrutiny.
Full-year organic growth moves to 6.5–7.0% from 8.3–9.3%; the quarter grew 7.7%.
Adjusted operating income is $1.706B versus $1.034B GAAP; the impairment is the largest quarterly add-back.
The goodwill charge reflects lower forecast cash flows, supply constraints and a longer recovery period.
Nine-month FCF is $2.698B before acquisitions; buybacks and dividends consume $2.012B.
The October CMR agreement proposes a $400M preferred-equity investment and U.S. distribution rights, subject to closing conditions.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | SYKStryker CorporationSnapshot 2026-11-11Financial period: 2026-09-30 |
|---|---|
| Market capMarket value, converted to USD | US$121.36B |
| Forward P/EProvider forward earnings estimate | 19.57x |
| EV / EBITDAEnterprise value / trailing EBITDA | 18.06x |
| Revenue growthLatest quarter vs prior-year quarter | 7.6% |
| Operating marginLatest reported quarter | 24.0% |
| Free cash flow yieldTrailing cash flow / market cap | 3.1% |
| Net debt / EBITDANet debt / trailing EBITDA | 1.62x |
| Debt / equityTotal debt / positive book equity | 0.66x |
| Trailing P/ETrailing twelve-month earnings | 33.95x |
| Price / bookPrice / positive book equity per share | 5.17x |
| EV / salesEnterprise value / trailing revenue | 5.16x |
| Earnings growthLatest quarter vs prior-year quarter | -11.7% |
| Gross marginTrailing twelve months | 65.7% |
| Net marginTrailing twelve months | 13.8% |
| Return on equityProvider trailing return; positive equity only | 16.0% |
| Free cash flow marginTrailing free cash flow / revenue | 14.1% |
| Dividend yieldIndicated annual dividend / price | 1.1% |
| Earnings payoutProvider trailing dividend payout | 37.5% |
| Current ratioCurrent assets / current liabilities | 2.18x |
| BetaProvider historical market sensitivity | 0.77 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q3 2026
Stryker grows organically but cuts guidance as acquisition economics and the gap between GAAP and adjusted profit demand scrutiny.
Research published November 10, 2026 · Download original report
Read Research PacketPresentation · 2026-11-10 · YouTube
Presentation · 2026-08-01 · YouTube
Presentation · 2026-05-01 · YouTube
Presentation · 2026-04-15 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
